Introduction
Successful gene therapy of disseminated diseases such as cancer requires efficient delivery vectors capable of targeting diseased cells following intravenous injection. Recombinant human adenoviruses are powerful vectors able to infect both proliferating and nonproliferating cells. However, several factors limit their effectiveness, notably the widespread distribution of the cellular attachment receptor CAR (coxsackie and adenovirus receptor) 1, 2 and internalization receptors, the a v b 3 and a v b 5 integrins, 3 which prevents selective targeting of tumour cells in vivo. Additionally, most of the population has been exposed to natural adenovirus infection, therefore recombinant adenovirus vectors are likely to encounter neutralizing anti-adenovirus antibodies in patient plasma. 4, 5 To avoid pre-existing humoral immunity in patients, several groups have investigated adenovirus serotypes from alternative species such as cows, [6] [7] [8] [9] [10] [11] [12] [13] [14] sheep, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] chimpanzees, [26] [27] [28] dogs [29] [30] [31] [32] [33] [34] [35] [36] and chickens. [37] [38] [39] [40] Chicken embryo lethal orphan virus (CELO; fowl adenovirus type 1), characterized as an infectious agent in 1957, 41 is attractive as a gene delivery vector since it is simple and cheap to produce in bulk in chicken embryos and has a good safety profile being completely replication defective in human cells, even in the presence of wild-type human adenovirus. 42 CELO is structurally similar to mammalian adenoviruses possessing an icosahedral capsid of 70-80 nm composed of hexon and penton proteins. Unlike most adenoviruses that possess a single fibre, CELO viruses carry two fibres protruding from each vertex. Fibre 1 is 42.5 nm in length and contains a sharp kink, while fibre 2 is 8.5 nm in length and straight. [42] [43] [44] [45] Although recombinant CELO has been demonstrated to transduce a range of mammalian cell lines and primary cells, [37] [38] [39] [40] in general, the level of transgene expression falls below that of adenovirus type 5 (Ad5) vectors when delivered at comparable multiplicity of infection.
Our laboratory has developed nongenetic modification of Ad5 by 'coating' virus with multivalent copolymers based on poly-[N-(2-hydroxypropyl)methacrylamide] (pHPMA). The polymer contains esters that react with amino groups on the surface of the virus forming a protective layer. Residual unreacted esters can then be employed for covalent linkage of targeting ligands that will bind receptor molecules on target cells.
Using this method Ad5 has been successfully retargeted with basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF). 46 We were therefore interested to determine whether this technology could be used for CELO virus, to attach a targeting ligand to infect mammalian cells via specific receptors and improve transgene expression.
In this study, we demonstrate that retargeting CELO with bFGF improves both binding and uptake of virus particles in human cells. Transgene expression was largely ablated by polymer coating; however, it could be re-established following the covalent linkage of bFGF to the surface of polymer-coated CELO virus with varying efficiency between cell lines. PC-3 cells that were poorly transduced by unmodified CELO virus generated 20-fold higher levels of transgene expression following the incorporation of bFGF. However, the specific transduction activity defined as the number of light units generated per internalized particle was lower for bFGF-pc-CELO than unmodified CELO. bFGF-pcCELOluc was resistant to neutralizing adenovirus serum in vitro, while the polymer extended circulation within the blood stream following systemic administration to mice, suggesting that it has potential as a delivery platform in humans.
Results

Transduction activity of CELO virus in human and chicken cells
Initially, we compared the transduction capability of CELOluc virus and Adluc in chick embryo fibroblasts (CEF) and four human prostate cell lines (Figure 1 ). The kinetics of CELOluc reporter gene expression were similar in both avian and human cells, increasing rapidly for 24 h and continuing to rise albeit more slowly up to 72 h (data not shown). CELOluc generated greater luciferase expression than Adluc in CEF, while overall Adluc gave greater transduction in all the prostate cell lines. The activity of CELOluc varied between the human cell lines, achieving up to 800-fold greater expression (at 250 particles/cell) in both DU-145 and PNT-2 cells compared with PC-3 and PNT1a cells, these latter cells only exhibiting dose-dependent transgene expression at the highest virus doses.
Immunocytochemical analysis of human CAR expression on prostate cells
Entry of CELO into avian cells is mediated via a specific avian cell surface receptor interacting with a domain located on fibre 2, a capsid protein unique to avian adenoviruses. However, while Coxsackie-adenovirus receptor (CAR) is the primary receptor for initial cell attachment for most human adenovirus serotypes, 1 it has also been demonstrated to act as a CELO virus fibre 1 receptor, permitting attachment to cells lacking the avian cell surface receptor. 38 Following staining with an antihCAR antibody, flow cytometry revealed that high levels of surface CAR expression in DU-145 and PNT-2 cells ( Figure 2 , Table 1 ) correlated with greater CELOluc transduction ( Figure 1 ) and likewise low CAR expression on PC-3 and PNT1a cells correlated with poor levels of CELOluc transduction.
Transduction activity of polymer-coated CELO virus
Previously we have shown that coating human Ad5 with amino-reactive polymers based on poly[N-(2-hydroxypropyl)methacrylamide] (pHPMA) bearing 4-nitrophenol groups (pHPMA-ONp) substantially reduced transduction. 46 To determine whether polymer coating CELO virus has the same effect, unmodified CELOluc or polymer-coated CELOluc (pc-CELOluc) virus were added to PC-3, PNT-2 and CEF cells at 1000 particles/ cell. CELO transduction of all cells was inhibited by polymer surface modification in a concentration-dependent manner (Figure 3 ). 
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Transduction activity of bFGF retargeted CELO virus
Retargeting polymer-coated Ad5 with bFGF has previously been shown to redirect virus uptake and transgene expression in cells expressing FGF receptors. 46 Using an ELISA kit (Dako, UK), polymer-coated Adluc was estimated to bind approximately 50 bFGF molecules (Fisher, personal communication) . bFGF contains 14 lysine residues that are potentially available to react with polymer-coated virus; however, it is likely that some attachments will occur via bFGF residues involved in FGF receptor binding, for example the side chain of Lys-21 of bFGF forms a hydrogen bond with the side chain of Gln-284 and Asp-282 of FGFR1. 47 We therefore examined whether bFGF could also retarget polymercoated CELOluc. The incorporation of bFGF onto pcCELOluc (bFGF-pc-CELOluc) restored transduction capability to varying extents in all cells tested ( Figure  4 ). The largest increase was observed in PC-3 cells with 470-fold higher transgene expression than pc-CELO (P ¼ o0.0001) and 13-fold greater than unmodified CELOluc (P ¼ o0.0001). In CEF, bFGF retargeting restored transgene expression to the level of the unmodified virus, while in PNT-2 cells, transduction although significantly greater than pc-CELOluc was less efficient than unmodified CELOluc.
The mean diameter of both Adluc and CELOluc, determined by photon correlation spectroscopy, increased following reaction with pHPMA-ONp from 115-119 to 121-125 nm. The addition of bFGF further increased size in a ligand concentration manner with 50 mg/ml bFGF giving rise to 128-130 nm particles. Despite these relatively small increases in size, the polydispersity of the virus population remained low suggesting that retargeted viruses remained as discrete particles and did not form large aggregates.
Confirmation of bFGF-mediated uptake of retargeted CELO virus
To confirm that transduction of PC-3 cells by bFGF-pcCELOluc was mediated by bFGF and not via fibre 1/ CAR interactions, virus infection was blocked with either excess Ad5 fibre protein or bFGF. Transgene expression from bFGF-pc-CELOluc was unaffected by CAR blockade, demonstrating that transduction occurred in a CARindependent manner (Figure 5a ), while luciferase activity from CELOluc fell 10-fold, indicating that the limited transduction properties of CELO virus in PC-3 cells were mainly CAR mediated. In contrast, CELOluc infection of avian CEF was not inhibited by competition with Ad5 fibre protein (Figure 5b ), suggesting that the Ad fibre does not bind to the avian receptor for CELO fibre 2.
Blockade of bFGF-pc-CELOluc uptake in PC3 cells with free excess bFGF led to a six-fold fall in luciferase expression (Figure 5c ), confirming that entry was mediated via the incorporated bFGF ligand. The presence of free bFGF had no effect on the level of transgene expression from unmodified CELOluc (data not shown).
Quantification of unmodified and retargeted virus internalization
In order to assess the specific transduction activity (defined as the number of luciferase light units per virus genome) of CELOluc and Adluc delivered via bFGF and CAR, levels of virus uptake into human and avian cells were determined by quantitative-PCR using two sets of primers and probes specifically designed to detect either Adluc or CELOluc sequences. Q-PCR was performed on lysed cells 90 min post infection to avoid both replication of CELOluc in CEF and degradation of virus in lysosomes, and compared with transgene expression at 48 h. To accurately assess the number of viruses taken up, cells were incubated at 371C permissive for binding and internalization, or 41C permissive for binding only. Surface bound virus was removed by washing the cells with 0.2 M acetic acid, which was confirmed since virtually no viruses were detected in acid-treated cells incubated at 41C (data not shown). In contrast for cells PNT-2 PC-3 CEF * * * * * * * * * * * * * * * * * * * * * * * * * * * * Figure PNT-2 PNT1a * * * * * * * * * * * * * * * * * * * * Figure 4 Transduction of avian and human prostate cells with bFGF-retargeted viruses. Polymer-coated-Adluc and pc-CELOluc were purified from free polymer by passage through Sepharose S-400 spin columns and incubated with 50 mg/ml bFGF on ice overnight. Unincorporated bFGF was removed using Microcon 50 000 MW filters and the viruses incubated with the cells at 300 particles/cell for 48 h. Cells were then lysed and luciferase activity measured. Relative light units (RLU) are expressed per mg/total protein. *P ¼ o0.05, **P ¼ o0.001, ***P ¼ o0.0001.
Retargeting of CELO virus M Stevenson et al
50-fold lower particle uptake than Adluc. Retargeting CELO with bFGF increased the number of particles taken up by PC-3 cells by 20-fold. In fact, all PC-3 cellassociated bFGF-pc-CELOluc viruses had internalized within 90 min, reflecting the efficient entry mechanism mediated by bFGF. However, the amount of bFGF-pcCELOluc cell association and uptake varied between cell lines exemplified by 10-fold more viruses binding to SKOV-3 than PC-3 cells, but only half as many being internalized. Flow cytometric analysis of PC-3 cells revealed expression of FGF receptors using an anti-FGFR1 antibody; however, no expression was detected on SKOV-3 cells ( Figure 6b , Table 2 ), suggesting that the high degree of bFGF-pc-CELOluc binding to SKOV-3 cells was nonspecific perhaps accounting for its poor internalization.
Comparison of specific activity demonstrated that human adenovirus generated more relative light units per internalized virus particle than bFGF-pc-CELOluc. In PC-3 cells nearly half as many bFGF-pc-CELOluc particles as Adluc particles were detected within cells, however the transgene expression level was 300-fold lower (Figure 6c ), resulting in a specific activity of 3700 RLU/virus particle for Adluc compared with 85 RLU/ virus particle for bFGF-pc-CELOluc. The specific activity of bFGF-pc-CELOluc was much higher in CEF with 5780 RLU/virus particle.
Transduction activity of CELO virus in the presence of human serum
Pre-existing neutralizing antibodies in patient sera may limit systemic delivery of Ad5. The neutralization of adenoviruses is type specific, and indeed the mammalian and fowl adenoviruses are not known to share any antigenic determinants. 48 Logunov et al. 39 demonstrated that the presence of preformed anti-Ad5 antibodies in mice did not affect the level of secreted alkaline phosphatase expression from CELO SEAP administered by intravenous injection. It was therefore to be expected that CELO virus would be resistant to inactivation by serum with known Ad5 neutralizing activity. While serum from three donors substantially attenuated Adluc transgene expression in PC-3 cells (Figure 7a Polymer coating provides some protection to Adluc against neutralizing antibodies (Figure 7c ). While there was little effect at the highest serum concentrations (1:10 dilution), the polymer coat did provide partial protection for bFGF-pc-Adluc when serum from D1 was diluted 1:100, shown by the 5.6-fold reduction in transgene expression from the polymer-coated virus compared with 160-fold reduction from unmodified Adluc. Similarly, Adluc exposure to serum from D2 diluted 1:100 halved transgene expression, whereas bFGF-pc-Adluc luciferase activity was unaffected.
Preincubation of bFGF-pc-CELOluc with serum, like unmodified CELOluc, had no effect on the transgene expression (Figure 7d ). Since repeated administration of CELO virus is likely to elicit an immune response, polymer coating will play an important role in extending blood stream circulation kinetics.
In vivo virus circulation kinetics in the presence of adenovirus neutralizing human serum Finally, we compared the pharmacokinetics of the various viruses in Balb/c mice in the presence of neutralizing serum from donor 1. To examine both the loss of circulating virus from the blood stream and transgene expression in various organs, immunocompetent mice were pretreated with clodronate liposomes temporarily depleting the pool of resident macrophages in the liver (Kupffer cells) and spleen, 49 allowing administration of a lower dose of virus (Green, personal (Figure 8a and b). Since the serum contains no CELO neutralizing antibodies (Figure 7b) , the difference in clearance of CELOluc and pc-CELOluc may be due to protection from opsonizing (non-neutralizing) factors. The clearance of retargeted viruses was subsequently examined albeit using a lower input dose. bFGF-pc-CELOluc showed circulation kinetics that were better than CELOluc (Figure 8c ) and similar to pc-CELOluc with 5% still in the bloodstream after 6 h. The organ distribution of the unmodified, polymercoated and bFGF-retargeted viruses after 6 h was similar with high levels in the liver, spleen and lungs and lower levels in the kidney and heart (Figure 8d and e). At this time only 5% of the input Adluc, 16% of the input pcAdluc dose and 20% of the input bFGF-pc-Adluc was detectable. In contrast, all input CELOluc, pc-CELOluc and bFGF-pc-CELOluc particles could be traced, suggestive of an altered intracellular fate. However despite high uptake of CELOluc and bFGF-pc-CELOluc particles in liver, spleen and lungs, transgene expression was very low compared with Adluc (Figure 8f and g ), suggesting that murine cells were nonpermissive for bFGF-pc-CELO transduction. Indeed in vitro, murine A9 fibroblasts infected with CELOluc generated very low levels of transgene expression (data not shown).
Discussion
CELO virus is a potentially effective gene delivery vector for systemic administration benefiting from a different profile of neutralizing epitopes to human adenoviruses. Despite previously being shown to transduce human lung, liver and kidney cells, 37, 38 it is limited by an inability to infect a broad range of mammalian target cells efficiently. However, this limitation provides a good vector platform due to reduced nonspecific infection of nontarget cells. In this study, we have shown that CELO transgenes can be efficiently expressed in prostate cells provided there is high-level CAR expression. Cells expressing low levels of CAR can be transduced by covalently modifying the virus to redirect uptake via receptors to an alternative ligand, bFGF. In addition, CELO virus is unaffected by exposure to adenovirus neutralizing serum from healthy donors, and has superior blood circulation kinetics in mice.
We demonstrated a correlation between human CAR expression and CELOluc transduction efficiency in human prostate cell lines (Figures 1 and 2) , confirming the findings of Tan et al. 38 that CELO virus has a CARdependent transduction behaviour mediated by fibre 1. Further examination showed that uptake of CELOluc was substantially less than Adluc (48-fold) in low CARexpressing PC-3 cells, despite only a four-fold difference in numbers of bound virus (Figure 6a) . The low uptake of CELOluc particles thus correlated with low level reporter gene expression observed in these cells.
To improve CELO internalization in low CAR-expressing cells, we modified the virus using a polymer coat to ablate virus/cell surface receptor interactions and provide a framework for the addition of the targeting ligand. Reaction with polymer resulted in reduced transgene expression in both human prostate and avian cells ( RLU/mg protein no serum cell control Figure 7 The effect of human serum on unmodified and polymer-coated virus transgene expression. Virus was incubated with diluted human sera for 30 min prior to application to cells. Virus was removed after 90 min and the media were replaced. Cells were lysed after 48 h and assayed for luciferase activity. 
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proteoglycans (HSPGs). However despite polymer modification, many particles were still able to gain entry to cells, shown by similar numbers of CELOluc and pcCELOluc particles detected within CEF, PC-3 and SKOV-3 cells after 90 min (Figure 6a ). Nevertheless, once inside greater numbers of pc-CELOluc were degraded, possibly in lysosomes, since fewer polymer-coated viruses than unmodified virus could be detected after 48 h (data not shown). This suggests that polymer coating decreased virus uptake into permissive cellular compartments. The observation that bFGF-pc-CELOluc reporter gene expression in CEF was comparable with unmodified virus (Figure 4 ) demonstrated that the attenuation of CELO virus transduction following polymer modification could be reversed by covalent attachment of a bFGF targeting ligand. Importantly, retargeting CELO with bFGF removed the dependence on CAR expression for transduction of human cells. Retargeting greatly increased virus internalization into PC-3 cells exemplified by all bFGF-pc-CELOluc particles bound to cells being taken up within 90 min compared with just 7% of bound CELOluc particles (Figure 6a ). This in turn led to 23-fold higher transgene expression from bFGF-pc-CELOluc compared with unmodified virus (Figure 5a ). However, despite the increased internalization, specific activity of the retargeted viruses was actually lower than the unmodified viruses, both for bFGF-pc-Adluc in PC-3 cells (data not shown) and bFGF-pc-CELOluc in CEF and PC-3 cells, suggesting that despite facilitating cell entry, once internalized the FGF pathway is less efficient in terms of generating RLU/virus than the CAR/integrin pathway.
Although bFGF retargeting significantly enhanced CELOluc transduction of PC-3 cells, Adluc remained the more efficient vector. Transgene expression from Adluc was 300-fold higher than bFGF-pc-CELOluc, despite only a two-fold difference in the numbers of particles internalized. The limiting step for efficient CELO virus transduction in human cells compared to avian cells would appear to occur inside the cell at the level of endosomal escape, virus disassembly, trafficking or transcription. Miyazawa et al. 50 demonstrated that the intracellular trafficking of Ad7 (subgroup B virus), which accumulates in late endosomes and Ad5 (subgroup C virus), which rapidly escapes early endosomes, varies due to differences in fibre structure involved in triggering pH-dependent membrane lysis and endosomal escape. More recently, Shayakhmetov et al. 51 demonstrated that virus binding of the chimeric Ad5/35L vector (an Ad5 vector expressing Ad35 fibre knob domains) to the Ad35 receptor caused the virus to remain in late endosomes for longer resulting in a large proportion being recycled back to the surface and ultimately less transgene expression than Ad5. Adenoviruses are susceptible to neutralization from preexisting immunity present in the majority of the human population limiting their use for systemic delivery. The transduction of CEF by CELOluc was not affected by exposure to human serum that greatly attenuated Adluc transduction (Figure 7 ). In addition, the fact that CELOluc demonstrated extended blood circulation kinetics compared to Ad5 confirms that CELO virus has potential as a delivery platform for systemic delivery in patients with pre-existing adenovirus immunity. However, repeat administration of CELO virus would be expected to give rise to anti-CELO neutralizing antibodies. Logunov et al. 39 demonstrated that CELOseap transgene expression was virtually eliminated when delivered intravenously to mice preimmunized with CELO virus. Therefore, the strategy of polymer modification known to bestow Adluc with some resistance to neutralizing serum in vitro and extended blood stream circulation in mice (Figures 7 and 8 ) could also play an important factor in improving pharmacokinetics of readministered CELO-based vectors. The polymer may also protect from components of the innate immune system since pc-CELOluc and bFGF-pc-CELOluc had increased circulation properties compared to the unmodified virus even in naïve mice.
Each of the viruses administered to mice were mainly localized in the liver, spleen and lungs. The numbers of CELOluc particles in these organs after 6 h was substantially higher than Adluc, which likely reflects the differential virus degradation over time. However, CELOluc transgene expression in mice organs was very low despite high levels of uptake reflecting the inefficiency of CELOluc to transduce murine cells; indeed, we have observed very poor transduction of murine A9 fibroblasts in vitro (data not shown). This is in contrast to recent studies that demonstrated SEAP 39 and GFP 52 expression in mice following i.v. administration; however, the doses delivered in these studies were 15-and 10-fold higher, respectively. FGF-retargeted transduction depends on high-affinity binding to FGFR rather than low-affinity binding to HSPG. 53 FGFR are downregulated in most tissues but highly upregulated on rapidly proliferating tumour cells or angiogenic endothelium. High bFGF-pc-CELOluc accumulation in liver, spleen and lungs may represent binding to HSPG and not FGFR resulting in poor transduction. Whilst providing proof of principal, FGF may not be the targeting ligand of choice for systemic delivery, since experience from i.v. administered FGF-pc-Adluc suggests the positively charged ligand can lead to excessive binding to human red blood cells (Fisher, personal communication) . Possible alternatives include vascular targets such as VEGF, or monoclonal antibodies such as herceptin or cetuximab. Further research into intracellular pathways will therefore be vital in selecting suitable ligands that will confer clinically relevant specific activity.
In addition, the safety of CELO vectors in humans requires further investigation. For adenovirus, E1A demonstrates transforming activity by inactivation of pRb and binding to p300/CBP, a family of proteins with histone acetylase activity. CELO possesses no homology for E1A, however CELO Orf22 interacts with p300 and Orf22 and Gam-1 bind pRb required for E2F activation allowing expression of S-phase-specific genes and host cell progression into S-phase. 54 The full identity of the transforming function is still being elucidated, however both Orf22 and Gam-1 are present in the vector employed in this study. A detailed analysis of the oncogenic potential of wt CELO and genetically modified CELO vectors is therefore required prior to clinical applications.
In summary, CELO-based vectors combine the properties of extended circulation and low transduction of nontarget cells, requiring appropriate targeting moieties to permit efficient transgene expression selectively in target human cells. pHPMA-ONp coating of CELO virus [55] [56] [57] SKOV-3 human metastatic ovarian adenocarcinoma cells (ATCC No. HTB-77) and primary chick embryo fibroblasts were each maintained in Dulbecco's minimal essential medium (DMEM) containing 10% fetal calf serum (fcs), 2 mM glutamine, 50 U/ml penicillin and 50 mg/ml streptomycin (GibCoBRL). CEF were prepared from 10-day-old embryos derived from specific-pathogen-free flocks (Henry Stewart & Co., UK). The head, internal organs and viscera were surgically removed and the body cavity thoroughly washed with PBS. Embryos were treated with prewarmed 0.25%/1 mM trypsin/EDTA solution for 45 min. Cell suspensions were filtered though gauze and incubated with 30 ml DMEM/10% fcs, 2 mM glutamine, Pen/Strep added to ablate trypsin activity. Cells were then pelleted, resuspended in fresh medium and routinely cultured for three passages.
Viruses
CELOluc (AIM 46) contains a deletion in the right end of the genome (41 731-43 684 bp) into which has been inserted a CMV IE enhancer/promoter-driven luciferase expression cassette 37 (a kind gift from Matt Cotten, Munich, Germany). Virus stocks were prepared by inoculating 10 8 CELOluc particles into the allantoic fluid of 9-day-old fertilized chicken eggs and incubating at 371C for 3 days. The allantoic fluid was collected and virus extracted using trichlorotrifluoroethane saturated with PBS, prior to purification by double banding on a CsCl gradient (CELO virus bands at a density of 1.35 g/ml). CELOluc was dialysed into 50 mM HEPES/ PBS, 10% glycerol pH 7.8 (storage buffer) and stored in small aliquots. Particle number was estimated using the pico green assay (Molecular Probes) assuming 1 mg/ml DNA ¼ 2.2 Â 10 10 particles/ml. Infectivity was measured by plaque assay in CEF; particle:infectivity ratios of 50-200 were routinely obtained.
Ad5luc (E1-, E3-deleted Ad5 expressing CMV IE promoter-driven luciferase) was grown in 293 cells until a cytopathic effect was observed. The virus was released from cells by freeze/thawing, extracted with N-butanol and purified by double banding on a CsCl gradient. Adluc was then dialysed into storage buffer as described above. Particle numbers were estimated using the pico green assay assuming 1 mg/ml DNA ¼ 2.7 Â 10 10 particles/ml. 58 Infectivity was measured by plaque assay in 293 cells; particle:infectivity ratios of 50-200 were routinely obtained.
Ad5 fibre protein was purified from soluble antigen (SA) obtained from CsCl centrifugation gradients, initially using a DEAE Sepharose column (Amersham Biosciences, UK) and subsequently using a Mono Q anion exchange column (Amersham Biosciences, UK). Separated protein peaks were run on an SDS PAGE gel and analyzed by Western blot using a guinea pig antifibre antiserum 59 diluted 1:1000.
Virus modification
In all, 50 ml of CELOluc (5 Â 10 10 -1 Â 10 11 particles/ml) or Adluc (1 Â 10 11 -1 Â 10 12 particles/ml) in storage buffer was reacted with 10 ml of 30, 60, 90 or 120 mg/ml pHPMA-ONp (a random copolymer formed from monomers of N-(2-hydroxypropyl)methacrylamide (90 mol%) and methacryloyl-Gly-Gly-4-nitrophenoxy ester (10 mol%) weight average of 22 000) (Polymer Labs, UK) resuspended in water for 1 h at RT. Free polymer was removed by passage through a Sepharose S-400 spin column (Amersham Biosciences, UK). Optimum pH conditions were re-established by adding 4 ml of 1 M HEPES/20 Â PBS pH 7.8 prior to mixing with bFGF (a kind gift from Tissue Repair Company, CA, USA) at a final concentration of 50 mg/ml and incubating overnight on ice. Polymer-coated virus not retargeted with bFGF was also incubated overnight on ice to hydrolyze remaining ester groups. Unincorporated bFGF was removed using a Microcon 50000 (Millipore) filter device. Virus recovery was determined by pico green analysis of virus DNA content. 
Photon correlation spectroscopy
The physical size and polydispersity of unmodified, polymer-coated and bFGF-retargeted viruses were measured by dynamic light scattering using a Zetasizer 3000 (Malvern Instruments, Malvern, UK) equipped with a 50 mW internal laser. At least 10 measurements were obtained for each sample at 251C in HPBS at a scattering angle of 901 and analyzed by monomodal analysis. The machine was calibrated using 199 nm (76 nm) polymer beads (Duke Scientific Corp., USA).
Transduction assays
All transduction experiments were performed using 5 Â 10 4 cells seeded into a 24-well plate 24 h prior to the addition of virus. Cells were incubated with virus at 300 particles/cell (unless otherwise indicated) in 100 ml of low serum (2% FCS) medium at 371C. After 90 min, Retargeting of CELO virus M Stevenson et al 900 ml of complete (10% FCS) medium was added and cells were incubated at 371C for 48 h. Cells were lysed with Promega lysis buffer and the luciferase activity was determined using the Promega luciferase assay kit and Lumat LB9507 luminometer (Berthold Technologies, UK). The amount of protein in each cell lysate was determined using the Advance protein assay (Cytoskeleton, UK) and luciferase expression standardized for protein content.
Competition assays were performed using a slightly modified protocol in which cells were preincubated at 371C for 1 h with 50 mg/ml of adenovirus fibre protein or 1.4 mg/ml free bFGF prior to addition of virus for 90 min. The cells were washed with PBS, and 1 ml of complete medium was added and the cells were incubated at 371C for 48 h prior to measuring luciferase activity.
To determine the number of internalized virus particles, unmodified, polymer-coated or FGF-retargeted virus bound to the outside of cells was removed by addition of 200 ml of 0.2 M acetic acid/150 mM NaCl for 1 min at RT followed by three washes with PBS prior to cell lysis, DNA extraction and Q-PCR analysis.
Quantitative PCR
Virus DNA was purified from infected cell lysates (5 Â 10 4 cells) using the QiaAMP DNA mini kit (Qiagen, UK) according to the manufacturer's instructions. Q-PCR was performed using the following primer/probe sets; CELO virus fibre 2 forward primer, labelled with FAM and TAMRA. DNA was amplified using the thermal cycling conditions, 501C for 2 min, 951C for 10 min, followed by 40 cycles of 951C for 15 s and 601C for 1 min, generated in an Applied Biosystems 7000 Sequence Detection System. Subsequent analysis was performed using ABI Prism 7000 SDS Software. A standard curve for each virus was generated by spiking known quantities of Adluc or CELOluc into cell lysate and performing a serial dilution, followed by DNA extraction and Q-PCR amplification. Standards curves of polymer-coated virus and bFGF-retargeted virus were also generated, however no significant difference from unmodified virus was observed.
Neutralization assays
Blood was taken from three healthy human donors and placed in a vial in the absence of anticoagulant. Serum was collected, serially diluted with PBS and mixed with Adluc, bFGF-pc-Adluc, CELOluc or bFGF-pc-CELOluc for 30 min prior to application to cells. Virus was removed after 90 min, the cells washed with PBS and 1 ml of complete medium was added to the cells. Luciferase activity was determined after 48 h.
Pharmacokinetics
Two experiments were performed using Balb/c mice injected with 10 ml of human serum diluted 1/200 into PBS 16 h prior to administration of virus. At the same time to deplete the resident macrophages in the liver (Kupffer cells) and spleen, mice were treated with 200 ml clodronate liposomes. Clodronate liposomes containing dichloromethylene diphosphonate (Roche Diagnostics, Mannheim, Germany) were supplied by Nico van Rooijen (clodronateliposomes.org). In the first experiment, 2.35 Â 10 10 Adluc, pc-Adluc, CELOluc or pc-CELOluc particles in 100 ml of storage buffer were injected into the tail vein. In the second assay, 1.32 Â 10 10 Adluc, bFGF-pcAdluc, CELOluc or bFGF-pc-CELOluc particles in 100 ml buffer were administered. In each assay, 20 ml blood samples were taken at 2, 10, 30 and 360 min post administration of virus and diluted to a final volume of 200 ml in PBS. DNA was extracted using a GenElute Mammalian Genomic DNA kit (Sigma) according to the manufacturer's instructions. Standard curves were generated by spiking a known quantity of Adluc or CELOluc into blood samples and performing a serial dilution.
Organs were harvested from mice 6 h after virus administration and homogenized in PBS at 300 mg tissue/ml (Ultra Thurax T25 Homogeniser). Tissue homogenate was analyzed for luciferase activity using Bright Glow Luciferase Assay Reagent (Promega). For Q-PCR analysis, DNA was extracted from 20 mg of homogenized liver, kidney, lungs or heart and 10 mg of homogenized spleen using a Sigma GenElute Mammalian Genomic DNA extraction kit. Q-PCR controls were generated by spiking known amounts of Adluc or CELOluc into 20 mg of control liver, kidney, lung or heart tissue or 10 mg of spleen tissue.
